Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $160,720.17 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 4,017 shares of Castle Biosciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the transaction, the insider directly owned 87,715 shares in the company, valued at approximately $3,509,477.15. The trade was a 4.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $42.24 on Friday. The company’s fifty day simple moving average is $39.20 and its two-hundred day simple moving average is $28.33. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $43.01. The firm has a market cap of $1.23 billion, a PE ratio of -93.87 and a beta of 1.06. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. The firm had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. As a group, equities analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Analyst Upgrades and Downgrades

CSTL has been the subject of a number of recent analyst reports. Lake Street Capital upped their target price on Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a report on Monday, January 12th. Guggenheim upped their price objective on shares of Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, January 5th. BTIG Research raised their target price on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Finally, Robert W. Baird increased their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.00.

Institutional Trading of Castle Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of CSTL. Amundi lifted its position in Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after acquiring an additional 4,111 shares during the period. AQR Capital Management LLC increased its stake in shares of Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after purchasing an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after purchasing an additional 655 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Castle Biosciences in the 1st quarter worth approximately $366,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.